letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...7576777879808182838485...100101»
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome (clinicaltrials.gov) -  Mar 25, 2019   
    P3,  N=150, Recruiting, 
    Phase classification: P1b/2 --> P1/2 | N=106 --> 146 | Trial completion date: Dec 2020 --> Jun 2021 Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
    Enrollment closed, Enrollment change, Combination therapy, Metastases:  Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) -  Mar 20, 2019   
    P1/2,  N=25, Active, not recruiting, 
    Everolimus plus letrozole demonstrated clinical benefit and could be a valid treatment option for postmenopausal women recurring/progressing on prior endocrine therapy. Recruiting --> Active, not recruiting | N=40 --> 25
  • ||||||||||  everolimus / Generic mfg., sapanisertib (TAK-228) / Takeda
    Journal:  Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. (Pubmed Central) -  Mar 8, 2019   
    These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2- ABC. Among the many signaling transduction pathways, which are altered post everolimus resistance, targeting dual mTORC1/2 is a possible option for patients who have recurrent disease from previous everolimus treatment.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Enrollment open:  GOG-3026: Ribociclib and Letrozole Treatment in Ovarian Cancer (clinicaltrials.gov) -  Mar 6, 2019   
    P2,  N=51, Recruiting, 
    Initiation date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2019 --> May 2019 Not yet recruiting --> Recruiting
  • ||||||||||  samotolisib (LY3023414) / Eli Lilly
    Trial completion date, Metastases:  A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) -  Mar 5, 2019   
    P1,  N=130, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Mar 2021 --> Mar 2020
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Biomarker, Enrollment closed, Combination therapy, Circulating tumor DNA, Metastases:  PADA-1: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (clinicaltrials.gov) -  Mar 4, 2019   
    P3,  N=800, Active, not recruiting, 
    Trial completion date: Nov 2019 --> May 2021 Recruiting --> Active, not recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Enrollment change, Trial completion date:  HELEX: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (clinicaltrials.gov) -  Feb 19, 2019   
    P2,  N=128, Active, not recruiting, 
    Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Oct 2019 --> Jun 2020 N=96 --> 128 | Trial completion date: Jan 2018 --> Jan 2020
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Enrollment closed, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Feb 15, 2019   
    P1,  N=256, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Recruiting --> Active, not recruiting
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Feb 8, 2019   
    P2,  N=59, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Mar 2019 Trial completion date: Mar 2019 --> Dec 2021 | Trial primary completion date: Jan 2019 --> Aug 2021
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) -  Feb 8, 2019   
    P2,  N=48, Active, not recruiting, 
    Trial completion date: Mar 2019 --> Dec 2021 | Trial primary completion date: Jan 2019 --> Aug 2021 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Feb 2021 | Trial primary completion date: Jul 2019 --> Mar 2019
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Enrollment open, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Feb 4, 2019   
    P1,  N=270, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Recruiting
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date, Tumor mutational burden:  LEEomic: CompLEEment-1 Canadian Correlative Sub-Study (clinicaltrials.gov) -  Feb 1, 2019   
    P2,  N=150, Not yet recruiting, 
    Active, not recruiting --> Recruiting Trial completion date: Dec 2018 --> Apr 2019 | Initiation date: Oct 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Clinical, Journal:  MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. (Pubmed Central) -  Jan 27, 2019   
    The most frequent grade ≥ 3 adverse events in the abemaciclib versus placebo arms were neutropenia (23.9% versus 1.2%), diarrhea (9.5% versus 1.2%), and leukopenia (8.6% versus 0.6%). Abemaciclib plus a nonsteroidal AI was an effective initial treatment with an acceptable safety profile for HR+, HER2- ABC.